Pyxis Oncology, Inc. (NASDAQ:PYXS) CFO Acquires $174,146.00 in Stock

Pyxis Oncology, Inc. (NASDAQ:PYXS) CFO Pamela Ann Connealy bought 88,850 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was bought at an average cost of $1.96 per share, for a total transaction of $174,146.00. Following the transaction, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at $2,350,320.28. The trade was a 8.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Pyxis Oncology Trading Up 9.8 %

Pyxis Oncology stock opened at $2.01 on Friday. Pyxis Oncology, Inc. has a 12 month low of $1.56 and a 12 month high of $6.85. The stock’s 50 day moving average is $3.46 and its 200-day moving average is $3.53. The company has a market capitalization of $119.53 million, a price-to-earnings ratio of -1.95 and a beta of 1.27.

Analyst Upgrades and Downgrades

PYXS has been the topic of a number of recent analyst reports. Royal Bank of Canada boosted their price target on Pyxis Oncology from $7.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Stifel Nicolaus initiated coverage on Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price target on the stock. William Blair downgraded Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Stephens initiated coverage on Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Pyxis Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Hedge Funds Weigh In On Pyxis Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the company. MetLife Investment Management LLC grew its position in shares of Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after purchasing an additional 5,484 shares during the last quarter. Pier 88 Investment Partners LLC boosted its stake in shares of Pyxis Oncology by 7.0% in the third quarter. Pier 88 Investment Partners LLC now owns 121,610 shares of the company’s stock valued at $446,000 after buying an additional 7,910 shares during the period. Fullcircle Wealth LLC bought a new stake in shares of Pyxis Oncology in the second quarter valued at approximately $40,000. SG Americas Securities LLC bought a new stake in shares of Pyxis Oncology in the first quarter valued at approximately $59,000. Finally, Jane Street Group LLC boosted its stake in shares of Pyxis Oncology by 40.8% in the third quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock valued at $182,000 after buying an additional 14,349 shares during the period. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.